• Record quarterly sales for MetaXplore in Australia, up 88% vs PCP
• Breakthrough study results for MetaPanel in Australia, detecting pathogens often missed by routine tests
• Strong growth for MetaXplore test sales in the UK following full market access

Microba Life Sciences reported a strong finish to FY25, with continued growth and clinical adoption of its core diagnostic tests in Australia and the UK. In Australia, MetaXplore maintained its growth trajectory, achieving record quarterly sales, supported by landmark GI study results from over 4,600 patients. MetaPanel adoption also continues to build, with breakthrough study results showing its ability to detect gastrointestinal pathogens often missed by routine tests. In the UK, MetaXplore gained significant traction following the achievement of full market access at the end of May, with record results in June. The company also transitioned its supplement business to focus on higher-margin Invivo branded products, where it saw strong growth. Microba achieved unaudited FY25 revenue of $15.67 million, representing 30% growth on FY24, and completed a $14.5 million capital raise to fund its growth strategy and path to regional break-even points in FY26.

Microba expects FY26 growth to build across the financial year, aligned to the growth profile of FY25 stepping up each quarter, driven by increasing clinician adoption and higher usage aligned to planned key product feature releases.

Microba is focused on continuing to accelerate sales of its core testing products across Australia and the UK, and is optimistic about its FY26 growth trajectory. The company has also shifted its therapeutics business to focus on partnering opportunities, while maintaining its core intellectual property.